Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
about
Inhibiting heat shock factor 1 in human cancer cells with a potent RNA aptamerHsp90 Inhibitors for the Treatment of Chronic Myeloid LeukemiaTargeting Hsp90 in urothelial carcinomaActivity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.An RNA aptamer perturbs heat shock transcription factor activity in Drosophila melanogasterLung cancer in never smokersTumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerInduction of premature senescence by hsp90 inhibition in small cell lung cancerExpression-based in silico screening of candidate therapeutic compounds for lung adenocarcinomaCombined delivery of paclitaxel and tanespimycin via micellar nanocarriers: pharmacokinetics, efficacy and metabolomic analysisTargeting highly expressed extracellular HSP90 in breast cancer stem cells inhibits tumor growth in vitro and in vivo.Hsp90 and co-chaperones twist the functions of diverse client proteins.Dual inhibition of EGFR at protein and activity level via combinatorial blocking of PI4KIIα as anti-tumor strategy.Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitorCurcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humansA high-content biosensor-based screen identifies cell-permeable activators and inhibitors of EGFR function: implications in drug discovery.Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivoEGFR-mutated lung cancer: a paradigm of molecular oncology.Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance.Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growthExpression of heat shock protein (Hsp90) paralogues is regulated by amino acids in skeletal muscle of Atlantic salmon.A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies.New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.Multi-drug delivery to tumor cells via micellar nanocarriersmTOR/MYC Axis Regulates O-GlcNAc Transferase Expression and O-GlcNAcylation in Breast Cancer.Hsp90 molecular chaperone inhibitors: are we there yet?Sulforaphane attenuates EGFR signaling in NSCLC cellsAntitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangementNoncovalent assembly of targeted carbon nanovectors enables synergistic drug and radiation cancer therapy in vivo.Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33.Pharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycinWild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors.Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.Concomitant inhibition of HSP90, its mitochondrial localized homologue TRAP1 and HSP27 by green tea in pancreatic cancer HPAF-II cells.HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo.Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancerJAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitorsNatural product inhibitors of Hsp90: potential leads for drug discovery
P2860
Q21132046-E94B9AF2-6218-4E02-AD62-34BB1F20AFFDQ26771790-633176B7-DD98-4709-BE5E-306239EDE79EQ27023406-818F4C03-E940-442E-AE52-BC2E1C9D3F26Q27851585-AFFEB8D4-8B3D-4965-8310-5D28A97549D3Q28237753-814D7CFC-4C50-4CEC-A2FE-378D343363BFQ28386853-7C6A5903-B6E6-4279-B47C-2DB14D05E507Q28396304-8F001638-5552-47CD-93AE-BBB9ECA25ABCQ28474354-3A937334-83DF-4266-9F40-894DE5D9BF91Q28476794-6D3D6561-FC2C-4249-9E94-9F854A0ECA2CQ28487747-5E936D70-42E4-473E-B6C7-3C6FACF652CCQ30805174-B2F52D57-6AC0-47CD-8751-929C596BB8FCQ33607477-0513DA09-9129-4D9D-94EF-5778301D9008Q33632845-2F47B55D-D626-4CD0-83BA-94DA19008F03Q33810574-92F7074B-022C-4FEE-9BB5-797DAA60F404Q34000044-B9ABAF2E-1284-453B-B7D4-07275CFDF779Q34162151-AA9DF59D-7864-4698-B2D1-05FC1E155E2CQ34264284-4B55072B-8939-44E2-B15C-5CDF9BB9D2B8Q34400894-5246E375-0C90-4E5E-AB73-EB7059468DB1Q34406334-891007A2-277D-430E-9CBF-7F648A7DD0AEQ34570799-3AD61CF4-D720-4AF6-8460-9B49DF9B7D34Q34669979-FDC7C7AB-597D-4B5C-A260-0C3889B3221EQ34989937-B90DB32C-A0A1-4EC3-99E2-477A1F07F097Q35098333-B525371A-A376-41BF-B62D-B4D26D64BCCCQ35196345-8F34DAEA-A24F-408B-B771-27445812277CQ35269272-04A53501-E826-4729-9A6E-55C77448E108Q35611316-F20F2173-5397-4224-9DF6-649FDBD3FF00Q35655105-97C37630-B031-4E77-838B-23F12FC7EDB0Q35673332-49628826-DDD9-441D-A885-80019791CE5BQ35688071-67C20184-2736-4EA2-B175-1E6145616013Q35720969-D6DF6E36-8FA6-423C-9B44-6A43D6794741Q35856908-44BBE431-358A-489B-9587-D8DC85E799B9Q35894216-A590D974-C6E2-46BA-B1B7-F438D63DAFB6Q36174463-D37F7480-1A70-46EE-8737-450FC0AD5FD2Q36200403-DB02F4F7-EB00-484F-8B3A-8BCAC0656E30Q36357215-A9ABBA4B-A529-45B8-B719-DA2D21C4EE65Q36452803-958088C3-AA34-4498-A230-FEDEA3230EA3Q36729440-4E3534B5-AB8D-4C2A-B3DC-339F1B73B838Q37089778-90D5B127-3F3D-4600-BD11-EC473647CF21Q37107598-2D155596-5B93-438A-99A0-2D3C21E8FF8AQ37136710-89309404-13AC-4768-8705-1840F0237C7A
P2860
Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Inhibition of Hsp90 down-regul ...... R mutant tumors to paclitaxel.
@ast
Inhibition of Hsp90 down-regul ...... R mutant tumors to paclitaxel.
@en
Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor
@nl
type
label
Inhibition of Hsp90 down-regul ...... R mutant tumors to paclitaxel.
@ast
Inhibition of Hsp90 down-regul ...... R mutant tumors to paclitaxel.
@en
Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor
@nl
altLabel
Inhibition of Hsp90 down-regul ...... FR mutant tumors to paclitaxel
@en
prefLabel
Inhibition of Hsp90 down-regul ...... R mutant tumors to paclitaxel.
@ast
Inhibition of Hsp90 down-regul ...... R mutant tumors to paclitaxel.
@en
Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor
@nl
P2093
P2860
P1433
P1476
Inhibition of Hsp90 down-regul ...... R mutant tumors to paclitaxel.
@en
P2093
Ayana Sawai
Carlos L Arteaga
David B Solit
Mithat Gonen
Neal Rosen
Sarat Chandarlapaty
William Sellers
P2860
P304
P356
10.1158/0008-5472.CAN-07-1570
P407
P577
2008-01-01T00:00:00Z